EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the MTAP–PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities

Vassilis Genoud iD, Maxime Borgeaud iD, Mihaela Aldea iD, Thibaud Koessler, Alfredo Addeo iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag425 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, 2026. Verfasst von Vassilis Genoud und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Geneva University Hospitals, Geneva 1205, Switzerland. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Purine-Nucleoside Phosphorylase, Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homozygous deletion of MTAP, one of the most frequent somatic copy-number alterations in cancer, creates a context of synthetic lethal vulnerability. MTAP loss leads to the accumulation of MTA which partly inhibits PRMT5, and induces a dependency on residual PRMT5 activity; a dependency that can be pharmacologically exploited. This review describes the MTAP–PRMT5 synthetic lethal axis from molecular biology to clinical translation. First-generation non-selective PRMT5 inhibitors were limited by hematological toxicity and reduced potency in MTA-rich environments. Second-generation MTA-cooperative inhibitors, which overcome these constraints by selectively stabilizing the inactive PRMT5–MTA complex, are characterized by tumor selectivity. Early-phase clinical data for MTA cooperative PRMT5 inhibitors showed encouraging signals of efficacy with manageable safety profiles in early phase trials, establishing clinical proof of concept. Various agents have now entered next steps of clinical development either alone or in combination. In this review we also discuss the biomarker challenges, essential to patient selection, including the limitations of different methods, as well as emerging resistance mechanisms to PRMT5 inhibitors. Molecular testing standardization, pharmacodynamic endpoint integration, and prospective resistance characterization are identified as priorities for next phases of development of PRMT5 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesPurine-Nucleoside PhosphorylaseNeoplasmsHumansSynthetic Lethal MutationsAnimals

Stichwörter der Autor:innen

MAT2AMTAP deletionPRMT5 inhibitorsprecision oncologysynthetic lethality

Substanzen

Protein-Arginine N-MethyltransferasesPurine-Nucleoside Phosphorylase5'-methylthioadenosine phosphorylasePRMT5 protein, human

Autor:innen und Institutionen

  • Oncology Department, Geneva University Hospitals, Geneva 1205, Switzerland.
  • Department of Medical Oncology, Gustave Roussy, Villejuif 94800, France.

ORCID-Profile: Vassilis Genoud, Maxime Borgeaud, Mihaela Aldea, Alfredo Addeo

Zitieren

APA

Genoud, V., Borgeaud, M., Aldea, M., Koessler, T., & Addeo, A. (2026). Targeting the MTAP–PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities. The Oncologist. https://doi.org/10.1093/oncolo/oyag425

Vancouver

Genoud V, Borgeaud M, Aldea M, Koessler T, Addeo A. Targeting the MTAP–PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities. The Oncologist. 2026. doi:10.1093/oncolo/oyag425

BibTeX
@article{Genoud2026,
  author = {Genoud, Vassilis and Borgeaud, Maxime and Aldea, Mihaela and Koessler, Thibaud and Addeo, Alfredo},
  title = {Targeting the MTAP–PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag425}
}
Kostenlos starten →